DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair an imbalance of the microbiome. The company’s targeted topical therapeutics pipeline includes SM-020 for the treatment of seborrheic keratosis, SM-030 for the treatment of hyperpigmentation disorders of the skin, and DBI-001 & DBI-002 for the treatment of atopic dermatitis, tinea pedis, and onychomycosis. For more information, please visit www.dermbiont.com.
Company Details
- Employees
- 20
- Founded
- -
- Address
- 451 D St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- dermbiont.com
- HQ
- Boston, Massachusetts
Dermbiont, Inc. Questions
Dermbiont, Inc.'s website is dermbiont.com
Dermbiont, Inc.'s LinkedIn profile is https://www.linkedin.com/company/dermbiont
Dermbiont, Inc. has
20 employees.
View email and phone details for 20
employees at Dermbiont, Inc..
Dermbiont, Inc.'s industry is
Biotechnology Research
Dermbiont, Inc.'s top competitors are
Roivant,
Abbvie,
Cymabay Therapeutics,
Leo Pharma,
Olive Tree Capital,
Alto Pharmacy,
Amgen,
Vyne Therapeutics Inc.,
Brickbuilt Therapeutics Inc. (Acquired By Dermbiont, Inc.),
Arcutis Biotherapeutics, Inc. (Nasdaq: Arqt).
Dermbiont, Inc.'s categories are Biotechnology Research
Dermbiont, Inc.'s founding year is 2017
